Kurin Commends the CDC for Their Recent Publication on Blood Culture Contamination

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, commends the Centers for Disease Control and Prevention (CDC) for their just-released publication on blood culture contamination. The paper stresses the importance of reducing these preventable contaminations and highlights how devices, like Kurin, have been shown to be effective in this regard. The CDC specifically states: “There are devices that are commercially available that have shown promise in further reducing blood culture contamination rates. These devices initially divert a small amount of potentially contaminated blood and then collect blood for the blood culture.”

“We are pleased to see the CDC use their resources to address this serious clinical challenge” said Bob Rogers, CEO of Kurin, Inc. “The CDC cited the small amount of blood these devices use to prevent the initial blood from entering the blood culture bottle and thus reduce contaminations. The CDC also shared that the average contamination costs approximately $4500, showing there is a financial impact as well as negative health consequences from these contaminations. Kurin is the market leader because of its simplicity and the small amount of blood used, and we look forward to working in concert with the CDC on this important issue.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections.

The new document can be found at: https://www.cdc.gov/antibiotic-use/core-elements/pdfs/fs-bloodculture-508.pdf

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

ENA Welcomes Kurin to 2023 Corporate Engagement Council

/in ,

The Emergency Nurses Association on Tuesday announced its 2023 Corporate Engagement Council, which includes Kurin, Inc., as its newest member.

Created in 2019, the CEC brings ENA and industry leaders together with a focus on innovation and advances in emergency nursing education, advocacy and research. Council members also participate in dedicated sessions with ENA Board members and leaders centered on discussion of, and planning for, future initiatives to advance emergency nursing.

The 2023 Corporate Engagement Council includes: Bioexcel Therapeutics, BrainScope, Chamberlain University, Elsevier, HealthStream, Magnolia, Mednition, Stryker, Teleflex and now Kurin.

“ENA prides itself on having a strong relationship with industry partners who deeply value emergency nurses and the ways they provide care to patients,” said ENA President Terry Foster, MSN, RN, CEN, CPEN, CCRN, TCRN, FAEN. “Kurin’s emphasis on innovative, clinician-approved technologies makes it a great addition to the CEC.”

Kurin CEO Bob Rogers described a natural connection between Kurin and ENA, which he called a vital organization that provides leadership and a wide variety of resources to emergency department nurses.

“We are pleased to have received the invitation from the ENA to join its council,” Rogers said. “Kurin has become the market leader by providing an easy-to-use solution to reduce blood culture contamination and our goal is to work with the ENA to help their members improve clinical outcomes.”

For more information on ENA’s Corporate Engagement Council, visit ena.org/corporate-support/cec.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Successful FDA Audit

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced the results of their recent FDA inspection.

“I am pleased to announce Kurin has successfully passed an FDA inspection of our manufacturing procedures, records, and facilities,” said Bob Rogers, CEO and Inventor of Kurin. “In a recent unscheduled visit by the FDA, there were no observations of what are called a 483 non-conformance. We take pride in operating our company under Good Manufacturing Practices (GMP) and a robust Quality System. I am proud of our team for continuing to demonstrate our commitment to excellence and in consistently meeting federal requirements and our elevated expectations for quality.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, potentially exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Full Scale Manufacturing of Push-button Needle

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that their previously mentioned Advance Safety Needle System™ has entered full scale production on their automated machine. The Advance needle was tested in 2021, has been used in Kurin accounts since last year and is now widely available.

“We are pleased with the transition to automated manufacturing of the Advance Safety Needle, as market demand for alternative needles has been strong,” said Bob Rogers, CEO of Kurin, Inc. “Needle manufacturers have created significant stress in the supply chain with widescale backorders and unprecedented price increases. With our Advance needle, we can better control product availability for the growing Kurin customer base, as well as entertain inquiries from strategic partners looking for their own push-button needle. In addition, we are pleased that Advance shows improved performance characteristics compared to traditional, retraction-oriented products.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.

Kurin, Inc. Announces Launch of Its Proprietary Push-button Needle System

/in ,

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets announced that they have commenced the commercial launch of their push-button needle, to be used as part of Kurin blood culture sets. The Advance Safety Needle System was tested in 2021 and is now being sold into accounts using Kurin.

“We are proud to commercialize the Advance Safety Needle, as there has been market demand for alternatives and improvements in this space,” said Bob Rogers, CEO of Kurin, Inc. “We are pleased with our field trials performed over the past several months. In addition to the positive feedback that we received, our testing shows improved performance characteristics compared to traditional, retraction-oriented products. The development of the Advance Needle is an important milestone for Kurin, providing us a more reliable supply of product, better cost control, the opportunity to offer improved benefits over current needles, and creates new strategic opportunities in which we are already engaged.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.